- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -

- Only two categories of Grade 3+ treatment-related adverse events occurring in ≥10% of patients, both chemotherapy related -

- 84% of participants maintained or gained weight at three months -

- Global Phase 3 MAPKeeper 301 trial (NCT07562152) in first-line metastatic pancreatic cancer actively recruiting, with first patient dosing expected in mid-2026 -

- Company to hold investor conference call today, at 8:00 a.m. EDT -

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced updated clinical data from its ongoing Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

The data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (see Abstract #4013 and accompanying presentation) by Peter Vu, M.D., M.H.A., Associate Professor of Medicine and Medical Director, Cancer Quality, GI Medical Oncology, Experimental Therapeutics & Cellular and Regenerative Medicine at UC San Diego Moores Cancer Center. The presentation showcases data from an expanded cohort totaling 55 first-line pancreatic cancer patients.